Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China

Why It Matters

The deal gives Aligos a substantial cash infusion and upside potential while expanding a promising HBV therapy into the world’s largest hepatitis B market, accelerating its path to global commercialization.

Key Takeaways

• Aligos grants Amoytop exclusive rights for Greater China hepatitis B drug.
• Deal includes $25M upfront and up to $420M in milestones.
• Aligos retains US, EU, Japan, South Korea rights and China trial rights.
• Pevifoscorvir sodium faces tenofovir in Phase IIB SUPREME trial.
• High single‑digit royalties will flow to Aligos from Chinese sales.

Pulse Analysis

Chronic hepatitis B remains a major public‑health challenge, affecting over 250 million people worldwide, with China accounting for roughly a third of all cases. Existing therapies, such as tenofovir, suppress viral load but rarely achieve functional cure, creating a market appetite for next‑generation agents. Aligos Therapeutics has positioned pevifoscorvir sodium—a novel nucleos(t)ide analog—as a potential contender, leveraging its distinct mechanism to improve viral suppression rates. By targeting the Greater China region, the company taps into a market valued at over $2 billion in annual treatment spend, where pricing pressures and reimbursement pathways favor innovative, locally‑developed solutions.

The licensing arrangement with Xiamen Amoytop Biotech reflects a strategic split‑share model increasingly common among biotech firms. Aligos secures a $25 million cash advance and up to $420 million tied to clinical, regulatory, and sales milestones, while retaining lucrative rights in the U.S., EU, Japan, and South Korea. This structure de‑risks the costly Chinese development phase for Aligos, allowing Amoytop to leverage its regional expertise in regulatory navigation and market access. The high single‑digit royalty clause ensures Aligos benefits from any commercial success in China without diluting its global upside.

Looking ahead, pevifoscorvir sodium’s Phase IIB SUPREME trial pits the drug against tenofovir, the current standard of care. The second interim analysis slated for the second half of 2026 will be a critical inflection point for investors, as early efficacy signals could accelerate regulatory filings and broaden partnership opportunities. If topline data in 2027 confirm superior viral suppression or safety, Aligos could see a valuation uplift and a stronger negotiating position for future licensing or co‑development deals, while Amoytop stands to capture a sizable share of China’s hepatitis B treatment market.